Moderna Updates on Flu Program
Moderna Inc. announced ongoing support from the U.S. Department of Health and Human Services (HHS) to accelerate the development of mRNA-based pandemic influenza vaccines
The award was made thro' the Rapid Response Partnership Vehicle (RRPV) Consortium with funding from the Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Administration for Strategic Preparedness and Response (ASPR). The project will provide additional support for late-stage development and licensure of pre-pandemic mRNA-based vaccines. The agreement will also support the expansion of clinical studies for up to five additional subtypes of pandemic influenza.
In 2023, Moderna initiated a Phase I/II study to generate safety and immunogenicity data of an investigational pandemic influenza vaccine (mRNA 1018) in healthy adults aged 18 years and older. The study included vaccine candidates against H5 and H7 avian influenza viruses. Based on the positive preliminary data from the Phase I/II study, Moderna is preparing to advance mRNA 1018 into Phase III. The Company looks forward to sharing the Phase I/II results at an upcoming scientific meeting. This $590 million award has been funded in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), under Other Transaction Number: 75A50123D00005.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins